Late clinical-stage immuno-oncology company Genelux Corporation (NASDAQ:GNLX) revealed on Monday that it has been granted Fast Track designation by the US Food and Drug Administration (FDA) for Olvi-Vec (olvimulogene nanivacirepvec).
This designation relates to the treatment of patients with platinum resistant/refractory ovarian cancer.
"The Fast Track designation granted for Olvi-Vec underscores its potential to address unmet medical needs in ovarian cancer, a significant recognition as we continue to enrol our Phase 3 OnPrime study," commented Thomas Zindrick, president, vhairman and CEO of Genelux.
The ongoing Phase 3 trial is evaluating the efficacy and safety of Olvi-Vec in combination with platinum-based chemotherapy in patients with platinum-resistant/refractory ovarian cancer.
Fast Track designation expedites the drug development and review process for treatments targeting serious and life-threatening conditions. It includes regular engagements with the FDA review team and the possibility of eligibility for Priority Review and Rolling Review if specific criteria are met.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI